US Patent

US11413282 — Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor

Method of Use · Assigned to Genentech Inc · Expires 2033-09-06 · 7y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a combination therapy of a type II anti-CD20 antibody and a selective BCL-2 inhibitor for treating CD20-expressing cancer.

USPTO Abstract

The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective BCL-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

Drugs covered by this patent

Venclexta (venetoclax) · AbbVie

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3412`	—	Venclexta
`U-3412`	—	Venclexta
`U-3412`	—	Venclexta

Patent Metadata

Patent number: US11413282
Jurisdiction: US
Classification: Method of Use
Expires: 2033-09-06
Drug substance claim: No
Drug product claim: No
Assignee: Genentech Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.